to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Linda Van Le
Obstetrics and Gynecology - Gynecologic Oncology
Clinical or Medical
Interventional
Cancer (Ovarian)
Women's Health
25-0602
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
